Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia

Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia

Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology

Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology

Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate

Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2014 Financial Results

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2014 Financial Results

Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal

Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal

GlobeNewswire Press Release: Keryx Biopharmaceuticals, Inc.

GlobeNewswire Press Release: Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex(TM)

Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex(TM)

Keryx Biopharmaceuticals’ Zerenex(TM) Data Selected for Poster Presentation at the AMCP’s 26th Annual Meeting and Expo

Keryx Biopharmaceuticals’ Zerenex(TM) Data Selected for Poster Presentation at the AMCP’s 26th Annual Meeting and Expo

Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency

Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency

Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing

Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing

Keryx Biopharmaceuticals Appoints Greg Madison as Chief Operating Officer

Keryx Biopharmaceuticals Appoints Greg Madison as Chief Operating Officer

Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access

Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access

Keryx Biopharmaceuticals Announces Issuance of U.S. Patent for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate

Keryx Biopharmaceuticals Announces Issuance of U.S. Patent for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate

Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis

Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis

Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus and

Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus and